CRISPR Therapeutics

CRISPR Therapeutics

Biotechnologieforschung

Boston, MA 94.543 Follower:innen

Info

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Website
http://www.crisprtx.com
Branche
Biotechnologieforschung
Größe
201–500 Beschäftigte
Hauptsitz
Boston, MA
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2013
Spezialgebiete
Gene Editing, AAV, Hematology und Immuno-Oncology

Orte

Beschäftigte von CRISPR Therapeutics

Updates

Ähnliche Seiten

Aktien

CRSP

NASDAQ

Verzögerung von 20 Minuten

57,90 $

1,09 (1,919 %)

Aktiv
57,38
Niedrig
56,635
Hoch
58,84

Daten von Refinitiv

Mehr Informationen auf Bing

Finanzierung